Department of General Surgery, Hacettepe University Faculty of Medicine, Ankara-Türkiye.
Department of Radiology, Hacettepe University Faculty of Medicine, Ankara-Türkiye.
Ulus Travma Acil Cerrahi Derg. 2022 Dec;28(12):1696-1700. doi: 10.14744/tjtes.2022.84294.
Percutaneous cholecystostomy is an alternative or bridge to cholecystectomy (CCY) in high-risk patients with acute calculous cholecystitis. Our primary aim was to determine the parameters that could be used in interval CCY decision-making and to predict mortality in high-risk patients.
The medical records of 127 patients who underwent percutaneous cholecystostomy for acute calculous cholecystitis between 2010 and 2018 were retrospectively analyzed. The primary outcomes were the CCY rate and the factors affecting mortality in high-risk patients. Descriptive statistics and receiver operating characteristic analysis were performed using albumin and elective surgery.
Of the 127 patients undergoing percutaneous cholecystostomy, elective CCY was performed only in 43.1% of the high-risk patients. The 30-day and 1 year mortality rates were 11% and 17.3%, respectively. The American Society of Anesthesiologists' (ASA) score, Charlson comorbidity index (CCI), the negative predictive factors described in the Tokyo Guidelines 2018, the American College of Surgeons' (ACS) expected mortality rate, and albumin level were found to be significant factors affecting mortality and elective CCY probability. No mortality was observed, and an 82% elective CCY rate was achieved in patients whose albumin levels were higher than 3.16 mg/dL at initial presentation.
The plasma albumin level, ASA score, CCI, and ACS expected mortality rate can be used to predict mortality and decide on elective CCY. Percutaneous cholecystostomy is sufficient for resolving inflammation, but medical comorbidities determine the final condition of patients.
经皮胆囊穿刺引流术(PC)是一种替代或桥接手段,适用于伴有急性结石性胆囊炎的高危患者,使其能够接受胆囊切除术(CCY)。我们的主要目的是确定可用于间隔期 CCY 决策的参数,并预测高危患者的死亡率。
回顾性分析了 2010 年至 2018 年间 127 例行 PC 治疗的急性结石性胆囊炎患者的病历。主要结局为 CCY 率和高危患者死亡率的影响因素。使用白蛋白和择期手术进行描述性统计和接受者操作特征分析。
在接受 PC 治疗的 127 例患者中,仅对 43.1%的高危患者进行了择期 CCY。30 天和 1 年死亡率分别为 11%和 17.3%。美国麻醉医师协会(ASA)评分、Charlson 合并症指数(CCI)、2018 年东京指南中的阴性预测因素、美国外科医师学会(ACS)预计死亡率和白蛋白水平是影响死亡率和择期 CCY 概率的显著因素。在初始白蛋白水平高于 3.16mg/dL 的患者中,未观察到死亡,且择期 CCY 率为 82%。
血浆白蛋白水平、ASA 评分、CCI 和 ACS 预计死亡率可用于预测死亡率和决定择期 CCY。PC 足以缓解炎症,但医疗合并症决定了患者的最终状况。